Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favezelimab (MK-4280) Phase 1 in Advanced Solid Tumors
NCT02720068Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of favezelimab in solid tumor (18 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 1 more. Started May 2016; status: completed.
02
Drugs
favezelimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02720068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720068.